# Long-term Open-label Treatment of Moderate to Severe Glabellar Lines With CORETOX®

> **NCT04281745** · PHASE4 · UNKNOWN · sponsor: **Medy-Tox** · enrollment: 200 (actual)

## Conditions studied

- Glabellar Frown Lines

## Interventions

- **BIOLOGICAL:** CORETOX Inj

## Key facts

- **NCT ID:** NCT04281745
- **Lead sponsor:** Medy-Tox
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10-17
- **Primary completion:** 2020-06-17
- **Final completion:** 2022-03-16
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2020-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04281745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04281745, "Long-term Open-label Treatment of Moderate to Severe Glabellar Lines With CORETOX®". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04281745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*